biOasis Technologies, Inc., (BTI.TSXV & BIOAF.OTCQX) Presentation July 14

OTCQX BIOAF !TSX.V BTI July 2014

OTCQX BIOAF TSX.V BTI

Forward Looking Statements Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information.

Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com.

Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

2"


Market Profile OTCQX: BIOAF; TSX.V: BTI

3"

Data source: S&P Capital IQ Trailing twelve months as of Feb 28, 2014 Shares – June 23, 2014

52 Week Low-High ! $0.67 - $1.35 !(Jun. 23, 2014)

Shares Issued & Outstanding ! 41,963,130 "!Fully Diluted ! 48,485,405!Options !

"!6,272,275!($0.52 - $1.42) Directors, officers & employees

Warrants ! 250,000"!($0.575) Exp. 5/08/2016

Market Cap "! ~$52.9m !@ $1.26 Share Price (Jun. 23, 2014)

Cash Position $1,860,135 !(Feb. 28, 2014)

Ownership! Insiders & Affiliates ~35% !Institutional ~10%!


Who we are… Board of Directors Rob Hutchison, Chair & CEO!Former: CEO & Chief Scientist at eCharge Corporation (World’s First Internet Payment System) Chris Fibiger, PhD !Former: Head of Neuroscience, Amgen; VP Neuroscience, Eli Lily & CSO, Biovail Laboratories !Greg Gubitz, LLB !Former: VP, Biovail Corporation (merged Valeant Pharmaceuticals) COO, MDS Capital (Life Science VC firm $1bn under management) Terry Pearson, PhD!Professor: Biochemistry & Microbiology, UVIC Bench-mates: Nobel Laureate, Dr. George Kohler (monoclonal antibody) Discovered & commercialized highly- successful SISCAPA Assay Technology !!Ron Erickson !Over 30 years experience: attorney & senior level executive Current: Chair & CEO, Visulant Technologies (nano-photonics company) Michael Hutchison, QC, LLB!Partner, Smith Hutchison Law Corporation

Team!

!Judi Dalling, LLB, CFO !Over 35 years accountancy experience Seasoned public company CFO and corporate lawyer !Wilfred Jefferies, PhD, Founding Scientist !Oxford University, Molecular Immunology Discovered p97’s ability to cross the BBB & Ox26 (foundational antibody for BBB research) Professor: Microbiology & Immunology, UBC !Reinhard Gabathuler, PhD, Chief Scientist !University of Lausanne, Switzerland, Plant Biochemistry Over 25 years experience, academic research & early-stage biotech companies Former: VP Brain Research, Biomarin & CSO, Angiochem Inc. !Mei Mei Tian, PhD, Scientist !UBC, Microbiology and Immunology Expertise in BBB transport, cell biology, molecular biology !Laura Ho, MSc, Scientist !UBC, Microbiology and Immunology !Tiffany Tolmie, Corporate Communications !Honours, Wilfrid Laurier University


What we do… Brain Delivery Platform Patented “Transcend Family” of technologies allows drug therapies to penetrate the Blood-Brain Barrier (“BBB”) to treat diseases of the Central Nervous System (“CNS”) Potential treatments for:

Market Leading Technology

Transcend & Transcendpep ! 5"

Oncology Metabolic Diseases

Neurodegenerative Diseases


The Blood-Brain Barrier Challenge

Blood Brain Barrier Protective barrier of the CNS preventing toxic compounds from entering the brain from the circulatory system

Problem BBB prevents therapeutics from entering the brain

•  ~98% of small molecule drugs •  ~100% of large molecule drugs1

Solution Discovering a ‘carrier’ to deliver therapeutic treatments across the BBB

i.  Opportunity to extend patent life of existing drug therapies ii.  Contribute to the growth in CNS drug market and revitalize

dormant candidates iii.  Assist development of new therapies for currently untreatable

diseases

6"

1)  Royal Society of Chemistry

Tightly"woven"capillary"network"of"endothelial"cells"lining"the"blood"vessels"in"the"brain,"which"is"responsible"for"maintaining"homeostasis"


Breakthrough Solution

First Generation: Transcend •  Known as Melanotransferrin (MTf or p97) •  Native human protein found at low

concentrations in the blood •  Technology patented at University of British

Columbia; later purchased by biOasis

7"

The Transcend Family …is a naturally occurring physiological transport mechanism … acts as a ‘Trojan-Horse’ to transport therapeutics across the BBB and into the brain tissue

Second Generation: Transcendpep

•  A newly discovered peptide found within Transcend, which offers improved brain penetration over Transcend


Advantage of Transcendpep

�  Greater efficiency of BBB delivery �  Lower cost of production �  Improved quality control �  Simpler to link to therapeutics �  Transports a variety of compounds

with no apparent size limitation �  Extends biOasis patent portfolio �  Pharmaceutical collaborators

currently licensing Transcendpep

8"

BBB"

Transcendpep Therapeutic

Transcendpep in Action


Market Opportunities Major Unmet Medical Needs Drug market limited by the BBB

9"

A carrier to cross the

BBB would establish a foothold

within these major

markets

Central Nervous System

~$81.2bn

Neuro-degenerative

Diseases

~$20bn

!

Stroke & Traumatic

Brain Injury

~$7.5bn

Pain & Migraine

~$33.7bn

2014 Estimates in $USD

Clinical need met but improved BBB penetration could increase efficacy

Psychiatry

~$32.3bn

Infection (Bacterial, Viral, Fungal)

~$138bn

Lysosomal Storage Disease !

>$1.9bn


Brain Cancer Market Sales for Current Cancer Therapeutics Treatments for cancers, which frequently metastasize in the brain, Do Not cross the BBB in efficacious levels

10"

1)  GlobalData “Brain Tumor – Pipeline Assessment and Market Forecasts to 2017” released Jan. 17, 2011. 2)  Company Reported Data 3)  BT2111 Program Results slides 19 & 20

$0.9B

$2.1B

2009 2010 2011 2012 2013F 2014F 2015F 2016F 2017F

($ Billions)

Global Brain Tumor Therapies Market1

Herceptin® (trastuzumab)

HER2+ Breast Cancer

Rituxan® (Rituximab) lymphomas, leukemias

Taxol® (Paclitaxel) lung, ovarian,

etc.

Erbitux® (Cetuximab)

Metastatic colon cancer,

etc.

$92 million in sales 20132

$7.5 billion in sales 20132



Results Trancend + Trastuzumab (Herceptin®) conjugate not only crossed the BBB but increased cancer killing activities throughout the body3

Opportunity Potential to increase effectiveness of cancer therapeutics and treat tumours that metastasize in the brain

$1.4 billion Market in 2013


Multiple Development Opportunities Conjugated with Transcend: •  Antibodies •  Enzymes •  Biologics agents •  Small molecules drugs

Targeting:

11"

Patent Cliff Estimated ~$250 billion in lost revenue from patent expiration between 2012-20151

Transcend family linked with existing drugs offers the potential for patent term extensions through New Chemical Entity (“NCE”) "

Specific brain cells (e.g., neurons, astrocytes and glia)

Intracellular compartments (e.g., lysosomes, endosomes, mitochondria)

Delivery into the brain of existing therapeutic drugs currently not approved for CNS indications

Delivery into the brain of promising new agents in development

"""

1)"DeRuiter,"J.,"&"Holston,"P."L."(2012,"June"20)."Drug"Patent"ExpiraOons"and"the"“Patent"Cliff”."U.S."Pharm."2012;37(6)(Generic"suppl):12Y20.""


Transcend: Rapid Uptake in Brain

12"

Compound Brain Kin (mL-1/s-1/g-1)

Reference

Glucose 9.5 x 10-3 Smith (2003)

Transcend 6.4 x 10-4 Demeule et al. (2002) Morphine 2.0 x 10-4 Cisternino et al. (2001) Aprotinin ! 1.6 x 10-4 Demeule et al. (2008)

Insulin Rec Antibody ! 1.0 x 10-4 Pardridge (1997) Leu-Enkephalin 6.0 x 10-5 Zlokovic (1987) Morphine-6-Glucuronide 2.4 x 10-5 Temsamani et al. (2005) RAP ! 1.0 x 10-5 Pan (2004) Beta Amyloid 6.5 x 10-6 Banks (1991) DADLE 6.5 x 10-6 Chen (2002) TNF-α 4.3 x 10-6 Pan (2002)

Transport Efficiency

More

Less

In situ brain uptake – measurement of rate of transport

Com

petit

ors""


Independent 3rd party validation

Expand and protect

Intellectual Property portfolio

Advance internal

development programs

Collaborate with reputable pharmaceutical

companies

Corporate Strategy

13"

•  Low-cost projects •  Potential to achieve

major milestones: Short-Mid-Large Market Potential

•  Many “shots on goal” leading to commercial transactions with numerous strong partners or licensees

•  Over 30 patents granted relating to Transcend & Trancendpep for BBB delivery and neurodegenerative diseases

•  National Research Council

•  BC Cancer Research Centre

•  Texas Tech University Health Sciences Center


Development Programs

Completed 4 strategic collaborations on First Generation Transcend: •  Shire HGT •  AbbVie •  MedImmune •  UCB Pharmaceuticals

Second Generation Transcendpep: •  MedImmune executed License Agreement •  On-going discussion with AbbVie & UCB

Pharmaceuticals for licensing •  Further discussions with large

pharmaceutical companies on licensing and research opportunities

14"


Development Programs: Transcend + Anti-Amyloid Beta (“Aβ”) Antibody

Results !Transcend + anti-Aβ antibody conjugate increases transport into brain tissue by ~5-fold

0.000#

0.001#

0.002#

0.003#

0.004#

0.005#

0.006#

0.007#

Transcend3an43AB#mAb# an43Ab#mab#

Volume'Frac,o

n''' Parenchyma#

Quantitative Image Analysis by Laser Scanning Confocal Microscopy

15"

Alzheimer’s Disease Anti-Aβ antibodies have undergone clinical trials for treatment of Alzheimer’s disease Opportunity Using antibodies directed at Aβ are potential therapeutics for reducing amyloid plaques in the brain

National Research Council of Canada (NRC)

Anti-Aβ Transcend + Anti-Aβ


Development Program:Transcend + α-L-iduronidase (“IDU”)

Lysosomal Storage Diseases Rare inherited metabolic diseases caused by an enzyme deficiency primarily affecting children

Hurler Syndrome (MPS I) Problem •  MPS I is caused by an IDU deficiency •  Currently CNS effects untreatable Results •  Transcend + IDU (lysosomal enzyme)

conjugate increased IDU brain enzyme activity ~ 4-fold

Opportunity •  Offers promise of an enzyme replacement

therapy 16"

0"

0.2"

0.4"

0.6"

0.8"

1"

1.2"

IDU Transcend-IDU

Total"IDU

"acOvity" Capillaries

Parenchyma


Development Program:Transcend + iduronate-2-sulfatase (“IDS”)

Lysosomal Storage Diseases Rare inherited metabolic diseases caused by an enzyme deficiency primarily affecting children

Hunters Syndrome (MPS II) Problem •  MPS II is caused by an IDS deficiency •  Currently CNS effects untreatable Results •  Transcend + IDS (lysosomal enzyme)

conjugate increased IDS brain enzyme activity ~ 20-fold

Opportunity •  Offers promise of an enzyme replacement

therapy 17"

Native Enzyme

Transcend + IDS Enzyme


Development Program: Transcend + Doxorubicin

•  Doxorubicin is currently used as a cancer treatment (e.g. non-Hodgkin's lymphoma, multiple myeloma, acute leukemias, etc.)

Problem •  Currently does not penetrate the BBB

Results •  Significant INCREASE in brain uptake with

the Transcend + Doxorubicin conjugate VS Doxorubicin alone

Opportunity •  Would be highly effective in treating

brain tumors if it could be delivered into the brain

18"

0.00"

1.00"

2.00"

3.00"

Transcend-Doxo Doxo

% INJECTED DOSE (G TISSUE/G BODY MASS)*100%

Transcend Significantly Enhances Doxorubicin Transport into the Brain

Conjugate retains full activity once released in the brain


Transcend Significantly Reduces Doxorubicin Uptake into the Heart

Problem •  Doxorubicin’s most serious

adverse effect is life-threatening heart damage

Results •  Transcend + Doxorubicin VS

Doxorubicin on its own showed a significant DECREASE in uptake in the heart

Solution •  Could be used to treat brain

cancers and decrease heart-uptake side effect, offering increased usage

19"

0.0"

5.0"

10.0"

15.0"

20.0"

Transcend-Doxo Doxo

% IN

JEC

TED

DO

SE

(gra

m b

rain

tiss

ue/g

ram

bod

y m

ass)

*100


Development Program: Transcend + Trastuzumab (Herceptin®)

•  Trastuzumab (Herceptin®)1 is a humanized monoclonal antibody used to treat HER2+ breast cancer

•  Annual global sales ~$6.6 bn2

•  Increases survival rate but ~40% patients eventually develop breast cancer metastasis in the brain3

•  Trastuzumab (Herceptin®) does not cross the BBB

20"

1)  Herceptin® is a registered trademark of Roche/Genentech 2)  Company Reported Data – 2013 3)  Britta Weigelt, Johannes L. Peterse & Laura J. van't Veer. (2005, August). Breast

cancer metastasis: markers and models. Nature Reviews Cancer 5 , 591-602.

Brain Capillaries

Cell Nuclei

BT2111: Transcend – Trastuzumab (Herceptin®)

Confocal Image Performed by iCapture at St. Paul’s Hospital Vancouver Canada

BT2111 Program: Transcend + Trastuzumab (Herceptin®) conjugate Confocal Images Two Hours Post IV Administration


Reduced the number of HER2+ breast cancer tumors in the brain by 68%

The tumors that remained after treatment were 57% smaller

BT2111: Transcend + Trastuzumab (Herceptin®) In Vivo Efficacy in Breast Cancer Model

21"

…compared to those treated with Trastuzumab (Herceptin®) alone.

0"10"20"30"40"50"60"70"80"90"

Number of Tumors

0.0"

0.5"

1.0"

1.5"

2.0"

2.5"

Mean Tumor Volume

Transcend""(MTF"or"p97)"

mm

3!


Development Program: Transcendpep + siRNA

Small Interfering RNA (siRNA) •  Silences target genes •  Nox4 is a gene associated with human diseases (i.e. cancers, neurodegenerative diseases, metabolic diseases, etc.)

Problem •  siRNA does not cross the BBB •  Gene targeting within the brain is currently unachievable Results •  Transcendpep + siRNA conjugate delivered into the brain tissue •  Demonstrated ~2 fold decrease in Nox4 signal VS siRNA

alone Opportunity •  A potential cornerstone technology for the development of

new therapeutics suppressing disease-linked genes in the brain

22"

National Research Council

NO siRNA detected in Brain

Transcendpep + siRNA detected in Brain


Highlights

23"

Transcend Family

“…would be the first carrier to efficaciously shuttle compounds across the BBB”

Discovery of Transcendpep

•  Enhanced technology •  Greater commercialization

potential

Company Profile

•  Good cash position •  Clean share structure •  High internal ownership •  Strong IR Program •  Exit strategy in place

Management

Major success in: •  Drug commercialization •  Academia (BBB &

monoclonal antibodies) •  Biotechnology & venture

capital startups

IP & Collaborations

•  Full patent protection •  Large pharmaceutical

collaborations •  Positive results;

demonstrated efficacy

Large Market Opportunities

•  Ability to extend patent life •  Commercialize new

therapeutics and/or revitalize dormant candidates

•  Contribute to the growth in CNS drug market

Treatment Potential

•  Oncology •  Metabolic diseases •  Neurodegenerative diseases

…among others


Timeline 2014-2015 Milestones Achieved !  Proof of principle

demonstrated !  Discovery of

Transcendpep -extended patent protection

!  Strong pharmaceutical collaborations

!  Completion of necessary financings

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

Leader in providing shareholder value

Awarded TSX.V Top 50® "

Financing: TBD

Licensing: Transcendpep

Collaborations: New research and/or licensing agreements

External R&D: Development of New R&D Programs

Internal R&D BT2211 & LSD Programs Animal efficacy studies

Internal R&D Pre IND Toxicity Studies Proposed IND Filing

Evaluation: Exit strategies: Licensing / M&A

2014! 2015!

OTCQX BIOAF !TSX.V BTI July 2014

Documents

biOasis Technologies, Inc., (BTI.TSXV & BIOAF.OTCQX) Presentation July 14